ERA4TB accelerates the development of new treatment regimens for tuberculosis.

Effects of the COVID-19 on the fight against tuberculosis

The general public is well aware of the tragic impact of the COVID-19 on the community in terms of lives, disruption of livelihoods and social distress. Far less obvious are the indirect effects that the outbreak exert on other major diseases of global incidence like tuberculosis. To contain the spread of the COVID-19, most countries have imposed strict lockdown measures that, however necessary, are negatively affecting the programs to eradicate tuberculosis at global level by hindering TB diagnosis, notifications and likely shortening the provision of drugs against the infection.

The Stop-TB Partnership has been working on a series of models to estimate the effect of the COVID-19 outbreak on the progress of TB at global scale. These models focus on three countries with a high burden of TB and distinct social settings that constitute paradigmatic cases within the spectrum of countries in which TB has a high incidence. In the worst-case scenario, the modelers estimated that a 3-month lockdown followed by a 10-month period to return to normality could lead to an additional 6.3 million cases of TB between 2020 and 2025, and an additional 1.4 million TB deaths during this time at global level. With these figures, the gains made in the fight against TB in the last five to eight years could be lost out. The study stresses that recovering the progress made in the last years will only be possible through increasing the efforts and investments in TB.

ERA4TB stands in solidarity with the additional difficulties that the present situation imposes on patients and professionals involved in treating TB. ERA4TB is committed with the development of new drugs of easy administration and effectivity against resistant strains, the consortium hopes to help mitigate the consequences of the COVID-19 outbreak on the battle against TB.

ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for tuberculosis.

Objectives

The main objective of ERA4TB is to create a European open platform to accelerate the development of new regimens for the treatment of tuberculosis.

Ambition

All Member States of WHO and the UN have committed to the goal of ending the TB epidemic by 2030 through their unanimous endorsement of WHO’s End TB Strategy at the World Health Assembly and their adoption of the UN Sustainable Development Goals (SDGs).

Ambition

All Member States of WHO and the UN have committed to the goal of ending the TB epidemic by 2030 through their unanimous endorsement of WHO’s End TB Strategy at the World Health Assembly and their adoption of the UN Sustainable Development Goals (SDGs).

Structure

The ERA4TB platform is based on a progression pipeline that can cater for a variety of molecules at different stages of development.

News

Follow our articles and ERA4TB news

Press

ERA4TB participates in the #WorldEBHCDay campaign, ‘Partnerships for Purpose’

The article ‘How partnerships are driving new treatments for tuberculosis’ has just been published on World…
Event

ERA4TB 5th Consortium Meeting: First F2F meeting in Madrid after the pandemic

On June 20th and 21st the fifth Consortium Meeting took place in Madrid. The meeting…
Event

5th Consortium Meeting on 20th and 21st of June 2022 – After 2 years, ERA4TB meets again face to face in Madrid

More than 120 representatives of ERA4TB partners are meeting face to face with the occasion…

Twitter

Follow us and be the first
to know what we do

📨The 4th ERA4TB newsletter is now available!
Find out more about our in vivo activities in our interview with @BroschRoland, hear about our exciting new webinar series, and much more!

https://era4tb.org/newsletter-september-2022/

📢Did you know over 4 million TB cases remain undiagnosed each year? #WorldLungDay partners @EraseTb shines a spotlight on the vital importance of early detection and screening. Read more👇https://bit.ly/EraseTB #LeaveNoOneBehind #LungHealth

September 29th 16:00 CET Jess Potter @DrJessPotter & Goodman Makanda @MakandaGoodman @TBProof talk about what it means to be an advocate in the field of #tuberculosis and how advocates can contribute to research progress
https://www.tbnet.eu/post/tbnet-webinar-september-2022

TOMORROW! @LSHTM_TB Free & Open to all "Experts speak: what People with TB want researchers to know" https://www.lshtm.ac.uk/newsevents/events/experts-speak-what-people-tb-want-researchers-know#.Yyl1wfLPNbY.twitter

Load More...

Know how accelerate the development of new treatment regimens for tuberculosis, discover our project

The Project